Market Overview

IDEXX Laboratories: Q3 Earnings Insights



Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share increased 36.29% over the past year to $1.69, which beat the estimate of $1.42.

Revenue of $721,789,000 rose by 19.24% year over year, which beat the estimate of $669,450,000.


IDEXX Laboratories hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 29, 2020

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $444.96

52-week low: $168.65

Price action over last quarter: Up 7.88%

Company Overview

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States.


Related Articles (IDXX)

View Comments and Join the Discussion!

Posted-In: Earnings News